J Clin Oncol: Avapritinib vs. Regorafenib in the treatment of locally advanced unresectable or metastatic gastrointestinal stromal tumors: a randomized phase III study

Primary or secondary mutations of KIT or PDGFRA can lead to TKI resistance in most patients with gastrointestinal stromal tumors (GIST)
.

Avapritinib can selectively inhibit KIT and PDGFRA

Primary or secondary mutations of KIT or PDGFRA can lead to TKI resistance in most patients with gastrointestinal stromal tumors (GIST)

Patients were randomly assigned to avapritinib 300 mg/day or regorafenib 160 mg/day (taken for 3 weeks and rest for 1 week) at random 1:1
.

The primary study endpoint is PFS

Patients were randomly assigned to avapritinib 300 mg/day or regorafenib 160 mg/day (taken for 3 weeks and rest for 1 week) at random 1:1

The study included 476 patients, of which 240 were treated with avapritinib and 236 were treated with regorafenib

There was no significant difference in the median PFS between Avapritinib and regorafenib, which were 4.

PFS

PFS

At the time of the data cutoff, the median OS of the two groups was not yet mature
.

The 12-monthly assessed OS rates were 68.

At the time of the data cutoff, the median OS of the two groups was not yet mature

Efficacy evaluation

Efficacy evaluation

In any grade of treatment-related adverse events (TRAEs), the two groups were 92.
5% and 96.
2%, respectively
.

The proportions of TRAEs ≥3 were 55.

In any grade of treatment-related adverse events (TRAEs), the two groups were 92.

Adverse events

Adverse events

In summary, there is no statistically significant difference in PFS between avapritinib and Regorafenib (Regorafenib) in the treatment of locally advanced unresectable or metastatic gastrointestinal stromal tumors
.

In summary, there is no statistically significant difference in PFS between avapritinib and Regorafenib (Regorafenib) in the treatment of locally advanced unresectable or metastatic gastrointestinal stromal tumors
.

There was no statistical difference in PFS between avapritinib and Regorafenib for third-line or above treatment of locally advanced unresectable or metastatic gastrointestinal stromal tumors

Original source:

Kang YK, George S, Jones RL, et al.
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
J Clin Oncol.
2021 Aug 3: JCO2100217.
doi: 10.
1200/JCO .
21.
00217.
Epub ahead of print.
PMID: 34343033.

Kang YK, George S, Jones RL, et al.
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
J Clin Oncol.
2021 Aug 3: JCO2100217.
doi: 10.
1200/JCO .
21.
00217.
Epub ahead of print.
PMID: 34343033.
Leave a message here